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A B S T R A C T 
Background: Transcranial static magnetic field stimulation (tSMS) in humans reduces cortical excitability. 
Objective: The objective of this study was to determine if prolonged tSMS (2 h) could be delivered safely 
in humans. Safety limits for this technique have not been described. 
Methods: tSMS was applied for 2 h with a cylindric magnet on the occiput of 17 healthy subjects. We 
assessed tSMS-related safety aspects at tissue level by measuring levels of neuron-specific enolase (NSE, 
a marker of neuronal damage) and S100 (a marker of glial reactivity and damage). We also included an 
evaluation of cognitive side effects by using a battery of visuomotor and cognitive tests. 
Results: tSMS did not induce any significant increase in NSE or S100. No cognitive alteration was detected. 
Conclusions: Our data indicate that the application of tSMS is safe in healthy human subjects, at least 
within these parameters. 
Introduction 
Non-invasive brain stimulation (NIBS) techniques have made an 
important contribution to cognitive neuroscience and have been 
proposed as a treatment for neuropsychiatric disorders [1]. Repet-
itive transcranial magnetic stimulation (rTMS) and transcranial 
direct current stimulation (tDCS) are commonly used for NIBS in 
humans and animals. Recently we described that the application of 
transcranial static magnetic field stimulation (tSMS) in humans 
reduces the output of motor cortex — tested using TMS — for a few 
minutes after the end of stimulation [2]. Reduced motor output 
after tSMS can be explained by reduced motor cortex excitability. 
These results have been recently replicated by a different group [3 ]. 
tSMS using small magnets may thus be a promising tool to 
modulate cerebral excitability in a non-invasive, painless and 
reversible way. 
Static magnetic fields, unlike time-varying magnetic fields, are 
not associated with induced electric currents and have been shown 
to influence a variety of biological systems [4]. A number of studies 
suggest that static magnetic fields act primarily at the synapse and 
alter the function of membrane ion channels [5], and the applica-
tion of static magnetic fields to different animal preparations seem 
to have an effect that outlasts the time of stimulation [6]. When 
tSMS is applied in humans, the cortex is at least 2 cm away, so most 
of the strength of the magnetic field will not reach the target. The 
recommended limits by the World Health Organization (WHO) 
about safe exposure to static magnet fields are "time weighted 
average of 200 mT during the working day for occupational 
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Figure 1. Schematic representation of experimental set up. A. Magnet (MAG60r, Neurek SL, Toledo, Spain). B. Magnet location over the occipital cortex (Oz location of the 10-20 EEG 
international system), and an additional non-magnetic cylinder over the frontal cortex (Fpz location of the 10-20 EEG international system) to counterbalance the weight of the 
occipital magnet. C. Time course of the experiment. The experimental protocol is divided in five time points: baseline, during tSMS, postl, post2 and 24 h. 
exposure" (i.e. 8 h/day, 5 days/week) (http://www.who.int/peh-
emf/publications/facts/fs299/en/index.html). With the magnets 
we normally use in our lab (MAG45r and MAG60r; Neurek SL, 
Toledo, Spain), at 2 cm from the axis (the approximate distance 
from the scull to the cortex) the magnetic field is around 
150—200 mT [7], so within the safe limit proposed by the WHO. 
Moreover, many studies about safety of magnetic resonance 
imaging (MRI) techniques consider safe an exposure to magnetic 
fields >8T for experimental sessions that can last hours [8]. On the 
other hand, it cannot be excluded that the different gradient shape 
and/or the different magnetic field orientation may have different 
safety profiles. 
The purpose of this study was to test the safety of prolonged 
tSMS (2 h) of the occipital cortex in healthy volunteers to establish 
safety guidelines for future tSMS experiments and therapeutic 
trials. We tested the effects of tSMS on a cellular level, by 
measuring serum levels of neuron-specific enolase (NSE) and 
protein S-100 [9] — sensitive markers for neural or glial brain 
damage — in healthy volunteers before, during and after tSMS. In 
order to provide further evidence for the safety of tSMS, a battery 
of neuropsychological tests were performed to exclude cognitive 
adverse effects. Specifically, we chose the Mini Mental State Exam 
(MMSE) as an evaluation of global cognitive state [10], the 
Nine-Hole peg test (NHPT) to evaluate a fine motor task and 
visuomotor coordination, a two-choice reaction time test to assay 
attentional levels (and again visuomotor coordination). Verbal 
fluency, a cognitive process considered to be primarily frontal 
lobe-dependent, was tested to determine cognitive function 
associated to a brain location distant from the stimulated area [11 ]. 
Methods 
Subjects 
Seventeen healthy volunteers participated in this study (10 
males; mean age 34.4 ± 7.3 years; age range 24—45 years). 
Exclusion criteria were significant medical or psychiatric illness, 
pregnancy and concurrent use of neuroactive drugs. We also 
excluded individuals with pacemakers, brain stimulators, medica-
tion pumps or any type of metal object in the head including eyes — 
except for dental appliances or fillings — which might pose a 
physical hazard during tSMS. All subjects but one were right 
handed according to the Edinburgh handedness inventory [12]. The 
study was approved by the local ethical committee. Informed 
consent was obtained from all subjects. 
Experimental set-up 
Experimental set-up is shown schematically in Fig. 1. 
tSMS procedures 
To deliver tSMS we used a cylindrical Nickel-plated (Ni—Cu—Ni) 
NdFeB magnet of 60 mm diameter, 30 mm of thickness and a weight 
of 370 g (MAG60r, Neurek SL, Toledo, Spain). North magnetic field 
polarity was used (i.e. north pole was placed over the scalp). During 
the experiment, all subjects had tSMS over the occipital cortex (Oz 
location of the 10-20 EEG international system), and an additional 
non-magnetic cylinder was located over the frontal cortex (Fpz 
location of the 10-20 EEG international system) and remained fixed 
during the whole experiment to counterbalance the weight of the 
occipital cylinder. The non-magnetic cylinder was a steel nickel-
coated cylinder, had the same size, a weight of 368 g similar to the 
MAG60r (MAG60s, Neurek SL, Toledo, Spain). The cylinders were 
held in place with a leather strapping system (MAGlet60+, Neurek 
SL, Toledo, Spain). The tSMS was applied for 2 h. 
Blood samples for determining NSE and S-100 
We measured serum concentrations of NSE and S100, as sensi-
tive markers of neuronal damage and glial activation, respectively. 
Blood samples were taken in EDTA-free tubes from each subject at 
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Figure 2. Time course and concentration of serum levels of neuron-specific enolase 
(NSE) and protein S-100. A. Time course of NSE concentration (ng/ml). B. Time course 
of S-100 concentration (ng/ml). * = P < 0.05 (paired t-test). Error bars indicate standard 
deviations. 
baseline before the tSMS treatment was started (baseline), after 
60 min during the treatment (during), immediately after (postl), 
60 min after (post2), and 24 h (only 13 subjects) after the end of 
tSMS (post 24 h). A peripheral venous catheter in the left cubital 
fossa (or dorsum of the forearm) was maintained throughout the 
experiment to allow serial blood drawing (with the exception of the 
24 h blood sample that was obtained via new venipuncture). 
Samples were left 1 h at room temperature and 3 more hours at 4 °C 
to induce clot retraction. Crude sera were obtained by low-speed 
centrifugation (800xgj, and cleared-up by medium-speed centri-
fugation (5000xg). Aliquots were preserved at -20 °C until used. 
Serum NSE measurements were performed using the Quantikine® 
ELISA kit for Human Enolase 2/Neuron-specific Enolase (R&D Sys-
tems). S100 quantification was performed using the Human S100B 
ELISA kit (Millipore). In both cases, manufacturers' instructions 
were followed. 
In one subject, it was not possible to obtain blood samples 
during tSMS and in postl. In another subject, it was not possible to 
obtain blood samples in postl. Two samples during tSMS were 
excluded from the S100 analyses as outliers. Two additional sam-
ples in post2 were excluded from the NSE analyses because of a 
visually evident hemolysis (these samples were included in the 
S100 analyses). Thus, the final serum sample size (n) was: baseline 
n = 17, during n = 16 (n = 14 for S100), postl: n = 15, post2: n = 15 
(n = 17 for S100), 24h:n = 13. 
Assessment of cognitive and motor performance 
To detect possible side effects, the following investigations were 
performed before and after the tSMS testing on the same day. The 
neuropsychological test battery consisted of the Folstein Mini-
Mental Status Examination (MMSE) [10], and a phonemic Verbal 
Fluency Test [11 ] during which the letters F, A and S were presented 
with subjects required to say as many words beginning with the 
letter as possible during a 60 s period. Order of letter presentation 
was counterbalanced across subjects and conditions — pre- and post-
testing. Letter fluency scores were based on the number of correct 
items generated across the three letter conditions. The Nine-Hole 
peg test (NHPT) was performed to test fine motor skills (manipula-
tive dexterity) and complex visuomotor coordination with the right 
hand (this test was not performed with the left hand due to the 
presence of venous catheter). A two-choice Reaction Time (RT) test 
measured visuomotor speed. The subject was instructed to press the 
corresponding key to an arrow direction (pointing left or right) 
appearing on a screen as quickly and accurately as possible. The test 
consisted of three blocks, each with 120 trials. RTs and error rates 
were recorded, with the latter determined as a measure of accuracy 
to look for a possible trade-off between speed and accuracy. 
Statistical analyses 
Blood measures (NSE and S100) were compared to baseline with 
paired t-tests. Note that we purposely did not correct for multiple 
comparisons in order to conservatively maximize the possibility to 
find significant changes (P < 0.05). One-way ANOVA was employed 
to corroborate any unexpected significant findings. Cognitive 
measures were assessed with paired t-tests, except for data from 
the two-choice reaction time task, which were analyzed with a 
two-way repeated-measures ANOVA (with factors hand and time) 
to fully exploit the statistical power given by two hands. Values are 
given as mean ± standard deviation. 
Results 
The 2-h tSMS session was well tolerated by all 17 subjects. None 
of the subjects needed to interrupt or terminate the session due to 
side effects. One subject reported mild headache and numbness at 
the end of the tSMS, but was able to complete the study. 
Blood tests 
NSE concentrations were not affected by tSMS (Fig. 2A), neither 
during the stimulation (paired t-test, P = 0.74, n = 16), immediately 
after (postl, P = 0.58, n = 15), 1 h after (post2, P = 0.98, n = 15), nor 
24 h after (P = 0.92, n = 13). The average NSE concentration in 
post2, which represents the most relevant time point from a safety 
perspective, was 4.79 ± 2.14 ng/ml (baseline: 4.75 ± 3.12 ng/ml). 
S100 concentrations did not increase with tSMS (Fig. 2B). Inter-
estingly, S100 concentrations were actually significantly decreased 
both during tSMS (P = 0.0014, n = 14), immediately after tSMS 
(postl, P = 0.0166, n = 15) and 1 h after (post2, P = 0.0083, n = 17), 
but not 24 h after (P = 0.33, n = 13). The average S100 concentration 
in post2 was 9.98 ± 7.05 ng/ml (baseline: 14.11 ± 8.54 ng/ml). These 
decrease in S100 concentrations remained significant when the data 
were analyzed with a more conservative one-way ANOVA, either 
using repeated-measures design with only the 11 subjects for which 
all time points are available (F(4,40) = 5.7, P = 0.0009), or an 
independent-measures design with all subjects and all available time 
points (F(4,71) = 3.2, P = 0.0178). 
Cognitive tests 
In the two-choice reaction time task, RTs were faster with the 
right hand, as expected (two-way ANOVA, hand: F(l,16) = 24.0, 
P = 0.0002), but tSMS did not induce any significant effect (time: 
F(2,32) = 1.5, P = 0.24; interaction: F(2,32) = 1.5, P = 0.24; Fig. 3A). 
The number of errors made by the subjects during the task was 
slightly higher with the right hand (hand: F(l,16) = 4.8, P = 0.0440) 
and again was not affected by tSMS (time: F(2,32) = 1.3, P = 0.29; 
interaction: F(2,32) = 0.9, P= 0.41; Fig. 3B). 
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Figure 3. Time course of the cognitive assessment and motor performance. A. Time course of the Reaction Time (in milliseconds). B. Time course of the number of errors. C. Verbal 
Fluency Test. Time course of the total words counting. D. Time course of the Nine Hole Peg Test. * = P < 0.05 (paired t-test). Error bars indicate standard deviations. 
Word fluency was not impaired by tSMS (Fig. 3C). There was 
actually an improvement at postl (paired t-test, P = 0.0091) and at 
post2 (P = 0.0026), which was confirmed by a more conservative 
one-way ANOVA (F(2,32) = 7.9, P = 0.0016), probably reflecting a 
slight learning effect. 
The time to perform the NHPT was not affected by tSMS 
(P > 0.22; Fig. 3D). MMSE did not change after tSMS 
(baseline = 29.3 ± 1.1; postl = 29.6 ± 0.6; post2 = 29.6 ± 0.8; 
P > 0.33, data not shown in figures). 
Discussion 
The principal finding of this study was that 2 h of tSMS over the 
occipital cortex appears to be a safe procedure. 
There is currently no gold standard for assessing safety for NIBS 
protocols. At least three types of safety studies can be found in the 
NIBS literature: (i) studies that evaluate safety a posteriori (similarly 
to phase 4 clinical trials), assessing the incidence of possible 
adverse effects in large cohort of patients/subjects that already 
received specific NIBS protocols (e.g. Refs. [13—15]); (ii) studies that 
evaluate safety of a known NIBS protocol for its application to a new 
indication (similarly to phase 1 repositioning clinical trials), 
assessing the incidence of possible adverse effects in a small cohort 
of patients (e.g. Refs. [16,17]); (iii) studies assessing safety of a 
recently-introduced NIBS technique in healthy subjects (e.g. 
Ref. [18]). Our study belongs to the third group. 
The serum level of NSE is a marker of neuronal damage that has 
been previously used to assess NIBS safety [18—20]. No NSE changes 
have been reported with cathodal tDCS in 5 normal subjects [19], 
rTMS in 14 depressed patients [20] and rACS in 8 normal subjects 
[18]. We also found no changes in NSE levels either during or after 
tSMS in our experiments. Even though negative results always need 
to be considered with caution, our study was conservatively 
designed to achieve higher statistical power compared to previous 
NIBS safety studies (n = 15 for NSE at the most relevant time point, 
i.e. post2), in order to minimize the risk of type II error. 
We also measured serum levels of S100, a marker of glial dam-
age. Only one of the above NIBS safety studies assessed S100 levels, 
finding no changes [20]. Our a priori hypothesis was that if S100 
increased it would have suggested a glial damage and a safety 
hazard [21]. Surprisingly, we found that the S100 concentration 
decreased during and after the tSMS. This unexpected result might 
intriguingly suggest reduced glial reactivity, which could reflect a 
certain level of tissue protection [21]. However, it needs to be 
stressed that this is not a definitive finding, and should be 
confirmed in sham-controlled experiments in order to exclude non-
specific effects [22], which is beyond the scope of the present work. 
Even though we do not intend to make any strong claims about this 
unexpected S100 decrease, it does convincingly show that S100 
does not increase, strongly supporting the safety of our tSMS 
protocol. 
We observed no significant impairment in performance of 
visuomotor or cognitive tests. These tests are not typically included 
in previous NIBS safety studies, but are particularly important in our 
protocol given the significant behavioral effects recently reported 
with the application of tSMS to the visual cortex in monkeys [23]. It 
is important to note that we intended to exclude gross behavioral 
changes that would be hazardous for the everyday living. Indeed, 
because tSMS reduces cortical excitability, tSMS is expected to 
induce subtler behavioral effects associated with the execution of 
more complex visuomotor/cognitive tasks. 
In the present study, we did not perform EEG recordings, which 
were instead used in previous NIBS safety studies (e.g. Ref. [18]). 
The rationale for using EEG recordings to assess NIBS safety is 
because of the increased risk of seizures with protocols that in-
crease cortical excitability. tSMS was shown to reduce cortical 
excitability both in the sensorimotor cortex of humans [2,3,24], and 
in the visual cortex of cats and monkeys [23]. Decreased cortical 
excitability should reduce rather than increase the risk of seizures. 
In fact, it has been demonstrated that tSMS reduces epileptic ac-
tivity in animal models [25,26]. We therefore argue that EEG re-
cordings are not necessary to establish tSMS safety. 
Overall, the purpose of this study was to establish if tSMS could 
be delivered safely in humans in order to provide safe stimulation 
patterns for future experimental and therapeutic trials. We 
confirmed the safety of static magnet fields within the 
recommended limits reported by the WHO (http://www.who.int/ 
peh-emf/publications/facts/fs299/en/index.html). However, it 
cannot be excluded that stimulation parameters different from 
ours (different gradient shape, magnetic field orientation, dura-
tion, etc.) might have different safety profiles. 
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